Allergy Asthma Immunol Res.  2015 Mar;7(2):158-166. 10.4168/aair.2015.7.2.158.

Comparison of Intranasal Ciclesonide, Oral Levocetirizine, and Combination Treatment for Allergic Rhinitis

Affiliations
  • 1Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea. jhyoon@yuhs.ac
  • 2Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Konkuk University, Seoul, Korea.
  • 3Department of Otolaryngology, Ajou University School of Medicine, Suwon, Korea.
  • 4Department of Otorhinolaryngology-Head and Neck Surgery, The Catholic University of Korea, Seoul, Korea.
  • 5Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Kyungpook National University, Daegu, Korea.
  • 6Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Yeungnam University, Daegu, Korea.
  • 7Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, Korea.
  • 8Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, Kyunghee University, Seoul, Korea.
  • 9Department of Otorhinolaryngology, Pusan National University School of Medicine, Busan, Korea.
  • 10Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea.
  • 11Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 12Department of Otolaryngology, Chungnam National University School of Medicine, Daejeon, Korea.

Abstract

PURPOSE
To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).
METHODS
Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 microg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ).
RESULTS
Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination.
CONCLUSIONS
Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.

Keyword

Allergic rhinitis; ciclesonide; levocetirizine

MeSH Terms

Asthma
Estrogens, Conjugated (USP)
Humans
Nose
Pruritus
Rhinitis*
Rhinitis, Allergic, Seasonal
Surveys and Questionnaires
Estrogens, Conjugated (USP)

Figure

  • Fig. 1 Study flow and subject disposition. A total of 258 subjects aged ≥18 years successfully completed the study. Subjects were randomly assigned to treatment groups receiving 200 µg ciclesonide nasal spray, 5 mg oral levocetirizine, or a combination of both.

  • Fig. 2 Changes in efficacy parameters. Analysis of symptom severity was conducted using reflective total nasal symptom score (rTNSS) values recorded in patient diaries and averaged over the 2-week period. The rTNSS was calculated as the sum of four nasal symptoms: rhinorrhea, nasal itching, nasal congestion, and sneezing, each of which was rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activities) for the full analysis set (FAS) population. The Reflective total ocular symptom score (rTOSS) was calculated as the sum of three ocular symptoms: itchy eyes, red eyes, and watery eyes, each rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activities). physician-assessed overall nasal signs and symptoms severity (PANS) values were obtained from the investigators assessments of nasal signs (discoloration, swelling, discharge, and postnasal drip) and symptoms (rhinorrhea, itching, nasal congestion, and sneezing). Rhinoconjunctivitis quality-of-life questionnaires (RQLQ) was obtained via patient self-assessment of the 28 listed items. SD, standard deviation.

  • Fig. 3 Changes in efficacy parameters. Analysis of symptom severity was conducted using rTNSS (reflective total nasal symptom score) values recorded in patient diaries and averaged over the 2-week period. The rTNSS was calculated as the sum of four nasal symptoms: rhinorrhea, nasal itching, nasal congestion, and sneezing, each of which was rated on a scale of 0 (no signs/symptoms evident) to 3 (signs/symptoms causing significant discomfort that interfered with daily activities) for the full analysis set (FAS) population. The P values shown in the figure measure statistical significance between C (ciclesonide) vs L (levocitirizine) vs C+L (combination treatment) groups at P<0.05 through ANOVA. The P value for rhinorrhea was 0.0388, for itching 0.0429, for nasal congestion 0.0202, and for sneezing 0.4014. If a P value indicated statistical significance at P<0.05 within a scoring system, additional comparative analyses were performed in order to clarify which groups were responsible for the significance. Significant comparisons at the 0.05 level are indicated by asterisks (*) through multiple comparison analysis by Fisher's Least Significance Difference (LSD). Whiskers to the bars indicate SEM.

  • Fig. 4 Correlation analysis between rTNSS and PANS. Exploratory analysis for the correlation of rTNSS and PANS was conducted using Pearson's correlation analysis.


Cited by  1 articles

Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific Immunotherapy in Murine Allergic Rhinitis
Ji-Hyeon Shin, Do Hyun Kim, Boo-Young Kim, Sung Won Kim, Se Hwan Hwang, Joohyung Lee, Soo Whan Kim
Allergy Asthma Immunol Res. 2017;9(3):237-246.    doi: 10.4168/aair.2017.9.3.237.


Reference

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007; 28:3–9.
2. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126:466–476.
3. Postma DS, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001; 17:1083–1088.
4. Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005; 60:330–337.
5. Mutch E, Nave R, McCracken N, Zech K, Williams FM. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007; 73:1657–1664.
6. Stoeck M, Riedel R, Hochhaus G, Häfner D, Masso JM, Schmidt B, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004; 309:249–258.
7. Sunovion Pharmaceuticals Inc (US). Highlights of prescribing information. OMNARIS® (ciclesonide) nasal spray. Initial U.S. approval: 2006. Marlborough (MA): Sunovion Pharmaceuticals Inc.;2006.
8. Niphadkar P, Jagannath K, Joshi JM, Awad N, Boss H, Hellbardt S, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther. 2005; 27:1752–1763.
9. Ratner P, Jacobs R, Mohar D, Huang H, Desai SY, Hinkle J. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2010; 105:471–479.
10. Berger WE, Mohar DE, LaForce C, Raphael G, Desai SY, Huang H, et al. A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Am J Rhinol Allergy. 2012; 26:302–307.
11. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010; 104:13–29.
12. Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy. 2006; 36:676–684.
13. Chung YJ, Cho IK, Lee KI, Bae SH, Lee JW, Chung PS, et al. Seasonal specificity of seasonal allergens and validation of the ARIA classification in Korea. Allergy Asthma Immunol Res. 2013; 5:75–80.
14. Bousquet J, Annesi-Maesano I, Carat F, Léger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005; 35:728–732.
15. Fujieda S, Kurono Y, Okubo K, Ichimura K, Enomoto T, Kawauchi H, et al. Examination, diagnosis and classification for Japanese allergic rhinitis: Japanese guideline. Auris Nasus Larynx. 2012; 39:553–556.
16. Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013; 3:7.
17. Hojo M, Ohta K, Iikura M, Mizutani T, Hirashima J, Sugiyama H. Clinical usefulness of a guideline-based screening tool for the diagnosis of allergic rhinitis in asthmatics: the Self Assessment of Allergic Rhinitis and Asthma questionnaire. Respirology. 2013; 18:1016–1021.
Full Text Links
  • AAIR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr